Immunai Stock
Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
Sign up today and learn more about Immunai Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Immunai Stock
Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.
Funding History
May 2020 | $20.0M |
---|---|
February 2021 | $60.0M |
October 2021 | $215M |
Management
Chief Technology Officer and Co-founder
Luis F Voloch
Scientific Co-founder
Danny Wells
CEO and co-founder
Noam Solomon
Scientific Founder
Ansuman Satpathy
Scientific Founder
Dan Littman
Board Member
Eli Groner
Board Member
Robert Langer
Board memeber
Shahar Tzafrir
Chief Business Officer
Mark Jacobstein
SeniorAdvisor
Michael Aberman
Board Member
Zvika Orron
Board Member
Kenan Turnacioglu
Press
TechCrunch - Jan, 19 2024
TLV Partners raises new $250M fundbiospace - Jan, 19 2024
Israeli Biopharma Execs Vow Resilience, Anticipate Long ...dlvr - Aug, 18 2022
Immunai Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugslife-sciences-europe - Nov, 1 2021
Immunai–SEVERAL: investment, 202110 financing round Series B $215m led by Koch Disruptive Technologies